CHARACTERIZE CANCER
BRCA1 promoter methylation and pathogenic genomic alterations in homologous recombination and repair (HRR) genes are mutually exclusive in cancer patients.1-4
Identify More Patients
Identify more patients for PARPi therapy with BRCA1 promoter methylation.1
PARPi, poly (ADP-ribose) polymerase inhibitor.
InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
Promoter methylation biomarkers can
expand patient reach
or predict response.1,2
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma InfinityAI for BioPharma